Literature DB >> 15560058

The epidemiology of acute and chronic hepatitis C.

M J Alter1.   

Abstract

Although the incidence of newly acquired acute hepatitis C virus (HCV) infection has declined, an estimated 3.9 million Americans are chronically infected with HCV, most of whom are young adults who will be at risk of the severe consequences of their infection in the next 10 to 20 years. The relative importance of the two most common exposures associated with the transmission of HCV has changed over time. Blood transfusions, which account for a substantial proportion of HCV infections acquired more than 10 years ago, account for only a small portion of recently acquired infections. In contrast, injection drug use has accounted for a substantial portion of HCV infections during both the remote and recent past. Sexual exposures, which have been poorly ascertained particularly among patients with chronic hepatitis C, may account for 10% to 20% of HCV transmissions. Physicians and other health care professionals need to be educated not only about the appropriate medical management of HCV infected patients, but also about the known and potential risks for HCV infection, the need to ascertain complete risk behavior histories from their patients, the appropriate evaluation of high-risk patients for evidence of infections, and the recommendations for prevention.

Entities:  

Mesh:

Year:  1997        PMID: 15560058     DOI: 10.1016/s1089-3261(05)70321-4

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  33 in total

1.  Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.

Authors:  Fasiha Kanwal; Tuyen Hoang; Jennifer R Kramer; Steven M Asch; Matthew Bidwell Goetz; Angelique Zeringue; Peter Richardson; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2010-12-22       Impact factor: 22.682

2.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 3.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.

Authors:  Charitha Gowda; Todd T Brown; Charlene Compher; Kimberly A Forde; Jay Kostman; Pamela A Shaw; Phyllis C Tien; Vincent Lo Re
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

Review 5.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

6.  Self-assembling peptide nanotubes with antiviral activity against hepatitis C virus.

Authors:  Ana Montero; Pablo Gastaminza; Mansun Law; Guofeng Cheng; Francis V Chisari; M Reza Ghadiri
Journal:  Chem Biol       Date:  2011-11-23

7.  Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection.

Authors:  Pablo Gastaminza; Christina Whitten-Bauer; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-07       Impact factor: 11.205

8.  Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5' noncoding and nonstructural 5b genomic regions.

Authors:  Elisa Martró; Victoria González; Andrew J Buckton; Verónica Saludes; Gema Fernández; Lurdes Matas; Ramón Planas; Vicenç Ausina
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

9.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

10.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.